Monday, January 3, 2022

ImmunityBio Links With Amyris On COVID-19 Vaccines

Culver City-based ImmunityBio and Emeryville-based Amyris said today that the two companies are in a joint venture to commercialize a COVID-19 vaccine. Financial details of the deal were not announced. The two said they will combine their vaccine technology and manufacturing capabilities, with the target of completing human trials and delivering vaccines in 2022."